Lorence Kim
Managing Partner at Ascenta Capital
New York, New York
Overview
Work Experience
Co-founder and Managing Partner
2023 - Current
Ascenta Capital is a private equity and venture capital firm.
Independent Board Member
2022
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Raised $2,004,400,000.00 from Nextech Invest, Boxer Capital, Schroder Adveq, Cormorant Capital, Casdin Capital, Vivo Capital, Biotechnology Value Fund, Deerfield Capital Management, Third Rock Ventures and Fidelity.
Independent Board Member
2022
Cencora is a global healthcare company that advances the development and delivery of pharmaceuticals and healthcare products.
Raised $3,025,000,000.00.
Board Member
2021
Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.
Raised $95,000,000.00 from Bristol-Myers Squibb.
Board Member
2021
Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.
Raised $205,000,000.00 from GordonMD Global Investments, Boxer Capital, Third Rock Ventures, Nextech Invest, Invus, Eventide, Pavilion Capital Partners, Agent Capital, Casdin Capital and Shangbay Capital.
Independent Board Member
2022 - 2023
Sustainable Private Equity and Credit Investments
Venture Partner
2020 - 2022
Board Member
2014 - 2020
Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.
Raised $537,800,000.00 from Oaktree Capital Management.
Chief Financial Officer
2014 - 2020
Managing Director
2000 - 2014
Co-head of Biotechnology Investment Banking
Goldman Sachs is a multinational financial services firm providing securities, investment banking, and management services.
Education
AB, magna cum laude
1991 - 1995
MBA
1998 - 2000
Doctor of Medicine (MD)
1995 - 2000